[{"data":1,"prerenderedAt":105},["ShallowReactive",2],{"uc-org-bayer":3},{"organization":4,"includeUnpublished":14,"evidence":15},{"slug":5,"name":6,"country":7,"region":8,"industry":9,"wikidata":10,"records":11,"useCases":12,"indexable":13},"bayer","Bayer","DE","europe","pharma-and-life-sciences","Q152051",3,2,true,false,[16,54,81],{"title":17,"useCases":18,"organization":20,"vendors":21,"summary":24,"stage":25,"year":26,"channels":27,"languages":29,"metrics":31,"outcomeDisclosed":13,"sources":42,"verification":46,"grade":49,"id":50,"useCaseTitles":51},"Bayer France: MyGenAssist drafts pharmacovigilance follow up letters, with a measured time saving",[19],"adverse-event-case-intake",{"name":6,"anonymized":14,"country":7,"region":8,"industry":9,"wikidata":10},[22],{"name":6,"role":23},"in-house","Bayer's French pharmacovigilance department used MyGenAssist, an internal assistant based on ChatGPT, to draft the documentation request letters that officers send to reporters of spontaneous adverse event reports. The officer reviews and edits each draft. In a cross over study over four months, 122 cases (48 without the tool, 74 with it) averaged 22.25 minutes without and 16.97 minutes with the tool. The recipients' answer rate did not change, and setting it up needed one 2 hour training session for the team.","pilot",2024,[28],"internal-tools",[30],"en",[32],{"kpi":33,"value":34,"unit":35,"qualifier":36,"period":37,"baseline":38,"claimant":39,"quote":40,"sourceUrl":41},"handling-time-reduction",23.3,"percent","exact","per case, drafting follow up documentation letters, over a four month study","22.25 minutes per case on average without MyGenAssist","organization","In this study, we demonstrated that the implementation of MyGenAssist to the pharmacovigilance case documentation process provided an average of 23.3% time saving on the task without any modification in the rate of answers.","https:\u002F\u002Fwww.ebi.ac.uk\u002Feuropepmc\u002Fwebservices\u002Frest\u002FPMC11933758\u002FfullTextXML",[43],{"url":41,"title":44,"publisher":45},"Assessment of the Efficiency of a ChatGPT-Based Tool, MyGenAssist, in an Industry Pharmacovigilance Department for Case Documentation: Cross-Over Study","Journal of Medical Internet Research (full text via Europe PMC)",{"level":47,"checkedAt":48},"source-verified","2026-11-11","B","bayer-mygenassist-pharmacovigilance-case-documentation",[52],{"slug":19,"title":53},"AI for pharmacovigilance adverse event case intake",{"title":55,"useCases":56,"organization":58,"vendors":59,"summary":63,"stage":64,"year":26,"channels":65,"languages":66,"metrics":67,"outcomeDisclosed":14,"sources":68,"verification":74,"grade":76,"id":77,"useCaseTitles":78},"Bayer: natural language self service analytics with Snowflake Cortex Analyst",[57],"governed-text-to-sql-analytics",{"name":6,"anonymized":14,"country":7,"region":8,"industry":9,"wikidata":10},[60],{"name":61,"role":62},"Snowflake","platform","Bayer uses Snowflake Cortex Analyst as the query generation service and a Streamlit chat interface to answer natural language questions over its enterprise data platform, alongside its existing dashboards. The first phase answered executive questions from sales vice presidents, such as the market share of a product last month, and it has since been extended to business unit analysts with row level data. No outcome figures are published.","production",[28],[30],[],[69],{"url":70,"title":71,"publisher":61,"date":72,"archivedUrl":73},"https:\u002F\u002Fwww.snowflake.com\u002Fen\u002Fblog\u002Fcortex-analyst-ai-self-service-analytics\u002F","Cortex Analyst: Paving the Way to Self-Service Analytics with AI","2024-08-15","https:\u002F\u002Fweb.archive.org\u002Fweb\u002F20260608134835\u002Fhttps:\u002F\u002Fwww.snowflake.com\u002Fen\u002Fblog\u002Fcortex-analyst-ai-self-service-analytics\u002F",{"level":47,"checkedAt":75},"2026-09-26","C","bayer-cortex-analyst-self-service-analytics",[79],{"slug":57,"title":80},"Governed text to SQL analytics assistant",{"title":82,"useCases":83,"organization":84,"vendors":85,"summary":88,"stage":89,"year":90,"channels":91,"languages":92,"metrics":93,"outcomeDisclosed":14,"sources":94,"verification":100,"grade":76,"id":102,"useCaseTitles":103},"Bayer: Genpact pharmacovigilance AI for adverse event case processing",[19],{"name":6,"anonymized":14,"country":7,"region":8,"industry":9,"wikidata":10},[86],{"name":87,"role":62},"Genpact","In November 2018 Genpact announced a multi year agreement with Bayer under which its Pharmacovigilance Artificial Intelligence (PVAI) suite, which incorporates the Genpact Cora PharmacoVigilance software product, is applied to Bayer's existing pharmacovigilance database and IT systems. Bayer's head of pharmacovigilance said the partnership offered an opportunity to further increase the efficiency of its pharmacovigilance operating model and case processing, and Genpact said Bayer was among the first companies going live with the AI based Case Management module of the PVAI suite. Neither company has published outcome figures.","announced",2018,[28],[],[],[95],{"url":96,"title":97,"publisher":87,"date":98,"archivedUrl":99},"https:\u002F\u002Fmedia.genpact.com\u002F2018-11-01-Genpact-and-Bayer-to-Co-innovate-to-Leverage-Artificial-Intelligence-Capabilities-for-Patient-Safety","Genpact and Bayer to Co-innovate to Leverage Artificial Intelligence Capabilities for Patient Safety","2018-11-01","https:\u002F\u002Fweb.archive.org\u002Fweb\u002F20240616173231\u002Fhttps:\u002F\u002Fmedia.genpact.com\u002F2018-11-01-Genpact-and-Bayer-to-Co-innovate-to-Leverage-Artificial-Intelligence-Capabilities-for-Patient-Safety",{"level":47,"checkedAt":101},"2026-09-27","bayer-genpact-pharmacovigilance-ai",[104],{"slug":19,"title":53},1794496905866]